WWL70

Alpha/beta-hydrolase domain 6 (ABHD6) inhibitor

In mice, WWL70 guards against neuropathic pain stimulated by chronic constriction injury. It decreases the inflammatory response in the ipsilateral spinal cord, dorsal root ganglion (DRG) and sciatic nerve. WWL70 is considered as an anti-inflammatory therapeutic agent, that has the ability to prevent the synthesis of PGE2 (prostaglandin E2) and PGE2-G (PGE2-glyceryl ester).

WWL70 is a selective inhibitor of α/β-hydrolase domain-containing 6 (ABHD6), a serine hydrolase that acts as an alternative hydrolase of the endocannabinoid 2-arachidonoylglycerol (2-AG). It has an IC50 value of 55-70 nM and 90-95% inihibition of ABDH6. WWL70 hs been used in a variety of studies as an ABHD6 antagonist. It was shown to rescue impaired function of mGluR5 signaling, resulting in pain inhibition in arthritic rats. WWL70 was also used to show that ABHD6 is involved in brown adipose function and white adipose browning, and is a potential therapeutic target for obesity and type 2 diabetes.